Showing results (321-330 of 333) with videos related to
Sort By:
Pageof 34
Nature Communications|April 22, 2024
Prospective de novo drug design with deep interactome learningKenneth Atz, Leandro Cotos, Clemens Isert, et al.Journal of Medicinal Chemistry|May 25, 2013
Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malariaTiago Rodrigues, Filipa P da Cruz, Maria J Lafuente-Monasterio, et al.Nature Reviews Bioengineering|April 17, 2023
Engineering cytokine therapeuticsJeroen Deckers, Tom Anbergen, Ayla M Hokke, et al.Nature Reviews. Drug Discovery|December 6, 2019
Rethinking drug design in the artificial intelligence eraPetra Schneider, W Patrick Walters, Alleyn T Plowright, et al.Chemical Society Reviews|July 2, 2021
A critical overview of computational approaches employed for COVID-19 drug discoveryEugene N Muratov, Rommie Amaro, Carolina H Andrade, et al.Journal of Medicinal Chemistry|March 14, 2008
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesityLeo Alig, Jochem Alsenz, Mirjana Andjelkovic, et al.Journal of Medicinal Chemistry|January 5, 2002
Development of a virtual screening method for identification of "frequent hitters" in compound librariesOlivier Roche, Petra Schneider, Jochen Zuegge, et al.Nature Communications|November 25, 2025
Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimizationDavid F Nippa, Kenneth Atz, Yannick Stenzhorn, et al.Environmental Health Perspectives|February 25, 2016
CERAPP: Collaborative Estrogen Receptor Activity Prediction ProjectKamel Mansouri, Ahmed Abdelaziz, Aleksandra Rybacka, et al.Chimia|September 2, 2024
Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System ProjectsJohannes Aebi, Kenneth Atz, Simon M Ametamey, et al.Pageof 34